LLY
Eli Lilly and Company
NEW YORK STOCK EXCHANGE, INC.· Pharmaceuticals· US· IPO 1970-07-09
$1409.38
-1.61 (-0.11%)
last quote
Want the full multi-source brief on LLY?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$1409.38
High
$1437.00
Low
$1393.61
Previous close
$1410.99
Fundamentals
Market cap
$1.33T
P/E (TTM)
48.13x
P/S (TTM)
15.35x
P/B
38.29x
Gross margin
83.63%
Operating margin
40.34%
Net margin
31.90%
Rev growth (YoY)
45.51%
EPS growth (YoY)
50.65%
ROE
83.65%
52W high
$1449.68
52W low
$834.19
Beta
0.37x
Industry peers
by market cap
Upcoming earnings
next 30 days
2027-02-02in 89 daysbefore market
Q4 2026EPS est $11.16Rev est $24662.9M
Recent SEC filings
CIK 59478filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 3h
The Zacks Analyst Blog Highlights Lilly, Cisco, KLA, Oil-Dri Corp. of America and NVE
Lilly, Cisco and KLA lead five featured analyst reports, highlighting growth drivers ranging from GLP-1 demand and AI infrastructure to semiconductor advances.
SeekingAlpha · 5h
Eli Lilly: Higher Volume, Lower Realized Prices
Eli Lillyâs revenue surged on strong tirzepatide demand, but pricing and patent risks loom. Click here to read an analysis of LLY stock now.
Yahoo · 15h
Top Analyst Reports for Eli Lilly, Cisco & KLA
Eli Lilly, Cisco and KLA lead today's featured research reports, with strong demand, AI-driven growth and expanding product opportunities supporting their prospects.
Yahoo · 16h
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite launching a new trial. When stock prices and headlines point in opposite directions across the sector, something beneath the surface deserves a closer look.
Yahoo · 17h
Raised Guidance Altering The Investment Case For Eli Lilly Stock?
Eli Lilly reported Q3 2026 sales of US$24.4b and net income of US$6.5b, raised full-year revenue guidance to a range of US$91b to US$92b, and released clinical data across obesity, diabetes, and oncology programs. Beyond headline incretin demand, Lilly is tying higher revenue guidance to heavy manufacturing investment, AI-supported Alzheimer’s research through the SpeechDx license, and a broad lat
Yahoo · 17h
Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. Whether the pipeline saves the story or the bears win depends on one upcoming FDA decision.
Yahoo · 18h
Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor
Key TakeawaysEli Lilly hit a record high on Friday after raising its 2026 revenue forecast to $91-$92 billion, lifting its market value to about $1. 1 trillion, level with Berkshire Hathaway.
Yahoo · 19h
The U.S. Stocks Quietly Winning the Chinese Drug Boom
Many of the hot new drug candidates in the U.S. were developed by Chinese companies.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial